je.st
news
Tag: of
OneSubsea to supply subsea processing systems for Shells Stones development in Gulf of Mexico
2015-08-21 01:00:00| Offshore Technology
OneSubsea has secured a contract to supply subsea processing systems for the Shell Offshore Stones development in the Gulf of Mexico.
Tags: of
development
systems
mexico
Women's libido pill gets buyer excited to the tune of $1B
2015-08-20 20:28:14| Biotech - Topix.net
A Canadian pharmaceutical company has agreed to pay $1 billion for the developer of a recently approved drug that aims to boost a woman's libido, The Wall Street Journal reports.
Industry At A Glance: Are cow-calf returns enough to keep producers out of a cash trap?
2015-08-20 15:22:00| Beef
Prices in 2014 provided cow-calf producers unprecedented returns, sufficiently high enough to spur meaningful expansion. At least for the time being, cows are no longer being perceived as cash traps. read more
Industry At A Glance: Are cow-calf returns enough to keep producers out of a cash trap?
2015-08-20 15:22:00| Beef
Prices in 2014 provided cow-calf producers unprecedented returns, sufficiently high enough to spur meaningful expansion. At least for the time being, cows are no longer being perceived as cash traps. read more
New Analyses from the IMPROVE-IT Outcomes Study of VYTORIN (ezetimibe and simvastatin) and the TECOS Cardiovascular Safety Trial of JANUVIA (sitagliptin) Will Be Presented at the European Society of Cardiology Congress
2015-08-20 14:30:00| Merck.com - Product News
Dateline City: KENILWORTH, N.J. Additional Real-World Analyses from DYSIS and DYSIS II Assessing the Treatment of Dyslipidemia to be Presented KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, announced today that new analyses from the investigational IMPROVE-IT (IMProved Reduction of Outcomes: VYTORIN Efficacy International Trial) study of VYTORIN (ezetimibe and simvastatin), the TECOS (Trial Evaluating Cardiovascular Outcomes with Sitagliptin) cardiovascular safety trial of JANUVIA (sitagliptin), and real-world data from the Dyslipidemia International Study (DYSIS I and DYSIS II) will be presented at the upcoming European Socie Language: English Contact: MerckMedia:Pamela Eisele, 267-305-3558orKim Hamilton, 908-391-0131orInvestor:Justin Holko, 908-740-1879 Ticker Slug: Ticker: MRK Exchange: NYSE read more
Sites : [556] [557] [558] [559] [560] [561] [562] [563] [564] [565] [566] [567] [568] [569] [570] [571] [572] [573] [574] [575] next »